NCT01591356: EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: EphA2
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have EphA2 overexpression for dose expansion
Exclusions: CNS or brain metastases

Comments are closed.

Up ↑